UY32360A - Compuestos de etanamina y métodos de utilización de los mismos 545 - Google Patents

Compuestos de etanamina y métodos de utilización de los mismos 545

Info

Publication number
UY32360A
UY32360A UY0001032360A UY32360A UY32360A UY 32360 A UY32360 A UY 32360A UY 0001032360 A UY0001032360 A UY 0001032360A UY 32360 A UY32360 A UY 32360A UY 32360 A UY32360 A UY 32360A
Authority
UY
Uruguay
Prior art keywords
methods
same
ethanamine
compounds
ethanamine compounds
Prior art date
Application number
UY0001032360A
Other languages
English (en)
Spanish (es)
Inventor
Glen E Ernst
Bernstein Peter
Balestra Michael
Frietze William
John P Mccauley
Shen Lihong
Nugiel David
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32360(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY32360A publication Critical patent/UY32360A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)
UY0001032360A 2008-12-24 2009-12-23 Compuestos de etanamina y métodos de utilización de los mismos 545 UY32360A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24

Publications (1)

Publication Number Publication Date
UY32360A true UY32360A (es) 2010-07-30

Family

ID=42288011

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032360A UY32360A (es) 2008-12-24 2009-12-23 Compuestos de etanamina y métodos de utilización de los mismos 545

Country Status (31)

Country Link
US (4) US8013165B2 (cg-RX-API-DMAC7.html)
EP (2) EP2391606A4 (cg-RX-API-DMAC7.html)
JP (1) JP5491524B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110097996A (cg-RX-API-DMAC7.html)
CN (1) CN102333762B (cg-RX-API-DMAC7.html)
AR (1) AR074981A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009330745B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0923476A2 (cg-RX-API-DMAC7.html)
CA (1) CA2748235A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011001590A1 (cg-RX-API-DMAC7.html)
CO (1) CO6450688A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110365A (cg-RX-API-DMAC7.html)
CU (1) CU24017B1 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000205A (cg-RX-API-DMAC7.html)
EA (1) EA201190064A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011161A (cg-RX-API-DMAC7.html)
GT (1) GT201100186A (cg-RX-API-DMAC7.html)
HN (1) HN2011001773A (cg-RX-API-DMAC7.html)
IL (1) IL213518A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011006680A (cg-RX-API-DMAC7.html)
NI (1) NI201100131A (cg-RX-API-DMAC7.html)
NZ (1) NZ593282A (cg-RX-API-DMAC7.html)
PE (1) PE20120249A1 (cg-RX-API-DMAC7.html)
SA (1) SA109310013B1 (cg-RX-API-DMAC7.html)
SG (2) SG192510A1 (cg-RX-API-DMAC7.html)
SV (1) SV2011003962A (cg-RX-API-DMAC7.html)
TW (1) TWI442922B (cg-RX-API-DMAC7.html)
UA (1) UA106056C2 (cg-RX-API-DMAC7.html)
UY (1) UY32360A (cg-RX-API-DMAC7.html)
WO (1) WO2010074647A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105441B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013165B2 (en) * 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (cg-RX-API-DMAC7.html) 1973-05-26 1982-11-30
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US5455259A (en) 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
DE68925933T2 (de) 1988-08-12 1996-08-14 Fisons Corp Arylalkylamine und -amide mit krampflösender und nervenschützender Wirkung
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
SG47949A1 (en) * 1991-10-30 1998-04-17 Astra Ab 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
RU2128650C1 (ru) 1992-04-03 1999-04-10 Астра АБ (S)-α-ФЕНИЛ-2-ПИРИДИНЭТАНАМИН И ЕГО СОЛЬ С НЕОРГАНИЧЕСКИМИ КИСЛОТАМИ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ СУДОРОГ
JP4008033B2 (ja) * 1996-04-19 2007-11-14 ナームローゼ・フエンノートチヤツプ・オルガノン 置換ベンジルアミン及びうつ病の治療のためのその使用
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US8013165B2 (en) * 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545

Also Published As

Publication number Publication date
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
AU2009330745A1 (en) 2011-08-04
NZ593282A (en) 2013-06-28
JP2012513993A (ja) 2012-06-21
EP2391606A1 (en) 2011-12-07
EP2610246A1 (en) 2013-07-03
HN2011001773A (es) 2014-08-18
SG171928A1 (en) 2011-07-28
IL213518A0 (en) 2011-07-31
MX2011006680A (es) 2011-07-12
DOP2011000205A (es) 2011-07-15
GT201100186A (es) 2013-10-08
ZA201105441B (en) 2012-03-28
BRPI0923476A2 (pt) 2016-01-19
US20120277272A1 (en) 2012-11-01
CN102333762A (zh) 2012-01-25
CA2748235A1 (en) 2010-07-01
SV2011003962A (es) 2012-01-06
SA109310013B1 (ar) 2013-07-28
SG192510A1 (en) 2013-08-30
UA106056C2 (uk) 2014-07-25
CU24017B1 (es) 2014-07-30
EA201190064A1 (ru) 2012-02-28
CO6450688A2 (es) 2012-05-31
US8013165B2 (en) 2011-09-06
TW201028149A (en) 2010-08-01
KR20110097996A (ko) 2011-08-31
PE20120249A1 (es) 2012-04-19
WO2010074647A1 (en) 2010-07-01
US20130137731A1 (en) 2013-05-30
JP5491524B2 (ja) 2014-05-14
AR074981A1 (es) 2011-03-02
CN102333762B (zh) 2014-06-11
AU2009330745B2 (en) 2012-04-05
ECSP11011161A (es) 2011-07-29
TWI442922B (zh) 2014-07-01
CL2011001590A1 (es) 2012-06-22
NI201100131A (es) 2012-03-19
CU20110141A7 (es) 2012-01-31
CR20110365A (es) 2011-08-09
US9035065B2 (en) 2015-05-19
EP2391606A4 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CR11861A (es) Compuestos organicos
CO6351738A2 (es) Compuestos organicos
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
EA201170772A1 (ru) Органические соединения
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
SV2011003855A (es) Heteroarilos sustituidos
CR20120264A (es) Compuestos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
BR112012011328A2 (pt) inibidores de akt
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
PA8855001A1 (es) Monocarbamas
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
CO6341625A2 (es) Derivados de indol como agentes anticáncer
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
CO6321288A2 (es) Sales de compuestos inhibidores de vih
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
UY32360A (es) Compuestos de etanamina y métodos de utilización de los mismos 545

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190121